We are live on ! Find out more
Capital Research Global Investors

Capital Research Global Investors Portfolio holdings

AUM $717B
1-Year Est. Return 35.42%
 

Capital Research Global Investors (CRGI), a division of Capital Group established in 1931 and headquartered in Los Angeles, California, is a powerhouse in active investment management, overseeing hundreds of billions in assets with a focus on global equity portfolios. Known for its long-term, research-intensive approach, CRGI employs a unique multiple-portfolio-manager system to diversify risk and enhance returns, serving institutional clients, financial advisors, and individual investors through vehicles like the American Funds mutual fund family. The firm’s investment philosophy emphasizes fundamental analysis and a deep understanding of companies worldwide, aiming to identify growth opportunities over extended horizons. As part of Capital Group’s broader mission, CRGI has built a reputation for delivering consistent, value-driven results in the global investment landscape.

This Fund
S&P 500
This Quarter Est. Return
-15.35%
1 Year Est. Return
+35.42%
3 Year Est. Return
+133.7%
5 Year Est. Return
+183.13%
10 Year Est. Return
+734.77%
AUM
$321B
AUM Growth
-$84.1B
Cap. Flow
-$12.2B
Cap. Flow %
-3.79%
Top 10 Hldgs %
28.6%
Holding
461
New
21
Increased
187
Reduced
158
Closed
38

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$1.41B
2
XOM icon
ExxonMobil
XOM
+$937M
3
LLY icon
Eli Lilly
LLY
+$875M
4
TSLA icon
Tesla
TSLA
+$749M
5
GE icon
GE Aerospace
GE
+$740M

Top Sells

Rank Stock Value
1
JPM icon
JPMorgan Chase
JPM
+$1.99B
2
DB icon
Deutsche Bank
DB
+$1.49B
3
SCHW
Charles Schwab
SCHW
+$1.12B
4
AVGO icon
Broadcom
AVGO
+$1.12B
5
AMGN icon
Amgen
AMGN
+$1.06B

Sector Composition

Rank Sector Weight
1 Technology 19.51%
2 Healthcare 16.3%
3 Consumer Discretionary 11.31%
4 Industrials 10.9%
5 Financials 9.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
VLO icon
451
Valero Energy
VLO
$95.3B
-639,475
Closed -$64.9M
ZIMV
452
DELISTED
ZimVie
ZIMV
-156,278
Closed -$3.57M
NBIS
453
Nebius Group N.V.
NBIS
$72B
$0 ﹤0.01%
17,025,521
CZOO
454
DELISTED
Cazoo Group Ltd
CZOO
-1,118
Closed -$6.17M
PLAN
455
DELISTED
Anaplan, Inc.
PLAN
-195,000
Closed -$12.7M
DCUE
456
DELISTED
Dominion Energy, Inc. 2019 Series A Corporate Units
DCUE
-618,744
Closed -$62.8M
GNOG
457
DELISTED
Golden Nugget Online Gaming, Inc. Class A Common Stock
GNOG
-1,427,000
Closed -$10.1M
MGP
458
DELISTED
MGM Growth Properties LLC Class A common shares representing limited liability company interests
MGP
-11,363,182
Closed -$440M
AZPN
459
DELISTED
ASPEN TECHNOLOGY INC
AZPN
-504,050
Closed -$83.4M

Similar funds

Capital Research Global Investors's Q2 2022 Portfolio in Review

As of Q2 2022, Capital Research Global Investors held 461 positions worth $321B, down 21% from $405B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Capital Research Global Investors withdrew a net $12.2B in Q2 2022, closing 38 positions and reducing 158 holdings. Its most notable exit was Deutsche Bank, an estimated $1.49B position sold in full.

By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 21% a quarter earlier, followed by Healthcare and Consumer Discretionary.

Against the trend, Capital Research Global Investors opened a new position in Eli Lilly worth $945M.

  • Capital Research Global Investors's largest Q2 2022 buy was Eli Lilly: 2,914,107 shares worth $945M.
  • Capital Research Global Investors added most to AbbVie in Q2 2022, an estimated $1.41B increase.
  • Capital Research Global Investors's biggest Q2 2022 reduction was JPMorgan Chase, cutting an estimated $1.99B.
  • Capital Research Global Investors fully exited Deutsche Bank in Q2 2022, selling an estimated $1.49B.
  • Capital Research Global Investors's ten largest holdings make up 29% of its $321B portfolio in Q2 2022.
  • Capital Research Global Investors opened 21 new positions and closed 38 in Q2 2022.
  • Capital Research Global Investors's portfolio value fell 21% quarter-over-quarter to $321B.

Based on Capital Research Global Investors's 13F filing for Q2 2022, filed 15 Aug 2022.